P53 post-translational modification: Deregulated in tumorigenesis

Trends in Molecular Medicine

Volumn 16, Issue 11, 2010, Pages 528-536

  Dai, Chao ^a,b   Gu, Wei ^a  

^a Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; AUTOPHAGY; CARCINOGENESIS; CELL CYCLE ARREST; CELL METABOLISM; EPIGENETICS; HUMAN; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; TUMOR;

ACETYLATION; ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METHYLATION; NEOPLASMS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 78049302116     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.09.002     Document Type: Review

References (95)

1. Horn H.F., Vousden K.H. Coping with stress: multiple ways to activate p53. Oncogene 2007, 26:1306-1316.
2. Vousden K.H., Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007, 8:275-283.
3. Kruse J.P., Gu W. Modes of p53 regulation. Cell 2009, 137:609-622.
4. Green D.R., Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458:1127-1130.
5. Toledo F., Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 2006, 6:909-923.
6. Matsumoto M., et al. Posttranslational phosphorylation of mutant p53 protein in tumor development. Med. Mol. Morphol. 2006, 39:79-87.
7. Kruse J.P., Gu W. SnapShot: p53 posttranslational modifications. Cell 2008, 133(930-930):e931.
8. Li H.H., et al. A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J 2007, 26:402-411.
9. Bode A.M., Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 2004, 4:793-805.
10. Chao C., et al. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J. 2006, 25:2615-2622.
11. Taira N., et al. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol. Cell 2007, 25:725-738.
12. Olsson A., et al. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?. Cell Death Differ. 2007, 14:1561-1575.
13. Ichwan S.J., et al. Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells. Oncogene 2006, 25:1216-1224.
14. Feng L., et al. Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle 2006, 5:2812-2819.
15. Johnson T.M., Attardi L.D. Dissecting p53 tumor suppressor function in vivo through the analysis of genetically modified mice. Cell Death Differ. 2006, 13:902-908.
16. Bruins W., et al. The absence of Ser389 phosphorylation in p53 affects the basal gene expression level of many p53-dependent genes and alters the biphasic response to UV exposure in mouse embryonic fibroblasts. Mol. Cell Biol. 2008, 28:1974-1987.
17. Bruins W., et al. Delayed expression of apoptotic and cell-cycle control genes in carcinogen-exposed bladders of mice lacking p53.S389 phosphorylation. Carcinogenesis 2007, 28:1814-1823.
18. Bar J.K., et al. Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. Int. J. Gynecol. Cancer 2009, 19:1322-1328.
19. Matsumoto M., et al. Phosphorylation state of tumor-suppressor gene p53 product overexpressed in skin tumors. Oncol. Rep. 2004, 12:1039-1043.
20. Matsumoto M., et al. Prognostic significance of serine 392 phosphorylation in overexpressed p53 protein in human esophageal squamous cell carcinoma. Oncology 2004, 67:143-150.
21. Lee J.T., Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 2010, 17:86-92.
22. Brooks C.L., Gu W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 2006, 21:307-315.
23. Tasdemir E., et al. Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol. 2008, 10:676-687.
24. Marchenko N.D., Moll U.M. The role of ubiquitination in the direct mitochondrial death program of p53. Cell Cycle 2007, 6:1718-1723.
25. Itahana K., et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007, 12:355-366.
26. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 2006, 6:663-673.
27. Brooks C.L., et al. The p53-Mdm2-HAUSP complex is involved in p53 stabilization by HAUSP. Oncogene 2007, 26:7262-7266.
28. Meulmeester E., et al. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle 2005, 4:1166-1170.
29. Lu X., et al. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 2007, 12:342-354.
30. Wang X., et al. Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett. 2004, 561:195-201.
31. Ohkubo S., et al. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. J. Biol. Chem. 2006, 281:16943-16950.
32. Tang Y., et al. Acetylation is indispensable for p53 activation. Cell 2008, 133:612-626.
33. Marine J.C., et al. MDMX: from bench to bedside. J. Cell Sci. 2007, 120:371-378.
34. Yang W., et al. CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J. Biol. Chem. 2007, 282:3273-3281.
35. Yamasaki S., et al. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J. 2007, 26:113-122.
36. Chen D., et al. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005, 121:1071-1083.
37. Laine A., Ronai Z. Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene 2007, 26:1477-1483.
38. Kruse J.P., Gu W. MSL2 promotes Mdm2-independent cytoplasmic localization of p53. J. Biol. Chem. 2009, 284:3250-3263.
39. Shi D., et al. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16275-16280.
40. Duan W., et al. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J. Natl. Cancer Inst. 2004, 96:1718-1721.
41. Dornan D., et al. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 2004, 64:7226-7230.
42. Chen C., et al. Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene 2007, 26:2386-2394.
43. Chen C., et al. The amplified WWP1 gene is a potential molecular target in breast cancer. Int. J. Cancer 2007, 121:80-87.
44. Yuan J., et al. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 2010, 140:384-396.
45. Nijman S.M., et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005, 123:773-786.
46. Meulmeester E., et al. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol. Cell 2005, 18:565-576.
47. Kon N., et al. Inactivation of HAUSP in vivo modulates p53 function. Oncogene 2010, 29:1270-1279.
48. Li M., et al. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 2004, 13:879-886.
49. Masuya D., et al. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways. J. Pathol. 2006, 208:724-732.
50. Colland F., et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol. Cancer Ther. 2009, 8:2286-2295.
51. Rabut G., Peter M. Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008, 9:969-976.
52. Geiss-Friedlander R., Melchior F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 2007, 8:947-956.
53. Carter S., Vousden K.H. p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 2008, 7:2519-2528.
54. Bischof O., et al. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol. Cell 2006, 22:783-794.
55. Stehmeier P., Muller S. Regulation of p53 family members by the ubiquitin-like SUMO system. DNA Repair (Amst.) 2009, 8:491-498.
56. Xirodimas D.P., et al. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 2004, 118:83-97.
57. Abida W.M., et al. FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. J. Biol. Chem. 2007, 282:1797-1804.
58. Melchior F., Hengst L. SUMO-1 and p53. Cell Cycle 2002, 1:245-249.
59. Li T., et al. Expression of SUMO-2/3 induced senescence through p53- and pRB-mediated pathways. J. Biol. Chem. 2006, 281:36221-36227.
60. Yates K.E., et al. Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts. Aging Cell 2008, 7:609-621.
61. Sykes S.M., et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell 2006, 24:841-851.
62. Allis C.D., et al. New nomenclature for chromatin-modifying enzymes. Cell 2007, 131:633-636.
63. Krummel K.A., et al. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:10188-10193.
64. Feng L., et al. Functional analysis of the roles of posttranslational modifications at the p53C terminus in regulating p53 stability and activity. Mol. Cell Biol. 2005, 25:5389-5395.
65. Knights C.D., et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J. Cell Biol. 2006, 173:533-544.
66. Chao C., et al. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell Biol. 2006, 26:6859-6869.
67. Tang Y., et al. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 2006, 24:827-839.
68. Sykes S.M., et al. Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53. J. Biol. Chem. 2009, 284:20197-20205.
69. Luo J., et al. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408:377-381.
70. Luo J., et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
71. Cheng H.L., et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10794-10799.
72. Chen W.Y., et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005, 123:437-448.
73. Yamakuchi M., et al. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13421-13426.
74. Bradbury C.A., et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005, 19:1751-1759.
75. Huffman D.M., et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007, 67:6612-6618.
76. Hida Y., et al. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch. Dermatol. Res 2007, 299:103-106.
77. Kim J.E., et al. DBC1 is a negative regulator of SIRT1. Nature 2008, 451:583-586.
78. Zhao W., et al. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 2008, 451:587-590.
79. Firestein R., et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008, 3:e2020.
80. Deng C.X. SIRT1, is it a tumor promoter or tumor suppressor?. Int. J. Biol. Sci. 2009, 5:147-152.
81. Lain S., et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008, 13:454-463.
82. Barger J.L., et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008, 3:e2264.
83. Scoumanne A., Chen X. Protein methylation: a new mechanism of p53 tumor suppressor regulation. Histol. Histopathol. 2008, 23:1143-1149.
84. Jansson M., et al. Arginine methylation regulates the p53 response. Nat. Cell Biol. 2008, 10:1431-1439.
85. Sims R.J., Reinberg D. Is there a code embedded in proteins that is based on post-translational modifications?. Nat. Rev. Mol. Cell Biol. 2008, 9:815-820.
86. Chuikov S., et al. Regulation of p53 activity through lysine methylation. Nature 2004, 432:353-360.
87. Huang J., et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006, 444:629-632.
88. Shi X., et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol. Cell 2007, 27:636-646.
89. Huang J., et al. G9a and Glp methylate lysine 373 in the tumor suppressor p53. J. Biol. Chem. 2010, 285:9636-9641.
90. Huang J., et al. p53 is regulated by the lysine demethylase LSD1. Nature 2007, 449:105-108.
91. Ide T., et al. GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Mol. Cell 2009, 36:379-392.
92. Crighton D., et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006, 126:121-134.
93. Bensaad K., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
94. Feng Z., et al. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8204-8209.
95. Tasdemir E., et al. A dual role of p53 in the control of autophagy. Autophagy 2008, 4:810-814.